Instrument Inactif

Communiqués Anpath Group, Inc. OTC Bulletin Board

Actions

US03634J1060

Recherche biotechnologique et médicale

Cours en clôture OTC Bulletin Board Autres places de cotation
- ^USD	-

03/05/24	Telix Pharmaceuticals (Us) Inc. a conclu l'acquisition de QSAM Biosciences, Inc. (OTCPK:QSAM) auprès de Checkmate Capital Group LLC, Strategic Planning Assets Limited et d'autres.	CI
20/03/24	QSAM Biosciences, Inc. annonce ses résultats pour l'exercice clos le 31 décembre 2023	CI

Communiqués

16/04/24	QSAM ANNOUNCES REVERSE STOCK SPLIT RATIO AHEAD OF MERGER	AQ
16/08/23	QSAM Biosciences Provides Update to Shareholders on Phase 1 Progress and Preliminary Clinical Data	AQ
23/06/23	QSAM BIOSCIENCES, INC. : Unregistered Sale of Equity Securities (form 8-K)	AQ
14/06/23	QSAM Biosciences Adds the Nuclear Reactor at the University of Texas at Austin to its Radioisotope Production Supply Chain for its Bone Cancer Treatment Drug Candidate, CycloSam®	AQ
23/05/23	QSAM Biosciences Expands its Study of CycloSam® in the Treatment of Bone Cancer; Opens Patient Enrollment at Key Chicago Center, Insight Hospital and Medical Center	AQ
16/05/23	QSAM Biosciences and RLS Announce Clinical and Commercial Supply Agreement for Promising Clinical-Stage Metastatic and Primary Bone Cancer Treatment, CycloSam®	AQ
26/04/23	QSAM Biosciences Receives Second Key Patent in Europe for its Clinical Stage Radiopharmaceutical Drug Candidate, CycloSam®	AQ
11/04/23	QSAM BIOSCIENCES, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)	AQ
06/04/23	QSAM Biosciences Opens Enrollment of the Second Cohort of Patients in its Phase 1 Study of CycloSam Targeting Metastatic Bone Cancer	AQ
05/04/23	QSAM Biosciences Opens Enrollment of the Second Cohort of Patients in its Phase 1 Study of CycloSam® Targeting Metastatic Bone Cancer	AQ
04/04/23	QSAM BIOSCIENCES, INC. : Unregistered Sale of Equity Securities (form 8-K)	AQ
22/03/23	QSAM BIOSCIENCES, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)	AQ
20/03/23	QSAM Biosciences to Provide Updates on its Clinical Trial at the Emerging Growth Conference on Wednesday, March 22, 2023	AQ
08/03/23	QSAM Biosciences Receives Clearance from FDA to Expand Enrollment Criteria in its Phase 1 Study of CycloSam® Targeting Metastatic Bone Cancer	AQ
28/02/23	QSAM Biosciences Completes Enrollment of Initial Cohort in its Phase 1 Study of CycloSam® Targeting Metastatic Bone Cancer	AQ
22/02/23	QSAM Biosciences Recruits the Ellis Fischel Cancer Center at the University of Missouri as Clinical Trial Site to Further Expand and Advance the Study of CycloSam® for Bone Cancer	AQ
25/01/23	QSAM BIOSCIENCES, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)	AQ
23/01/23	QSAM Biosciences to Present at the Emerging Growth Conference on Wednesday, January 25, 2023	AQ
10/01/23	QSAM BIOSCIENCES, INC. : Other Events, Financial Statements and Exhibits (form 8-K)	AQ
10/01/23	QSAM Biosciences Provides 2022 Update and 2023 Milestones to Shareholders	AQ
18/11/22	QSAM BIOSCIENCES, INC. : Unregistered Sale of Equity Securities, Change in Directors or Principal Officers, Financial Statements and Exhibits (form 8-K)	AQ
15/11/22	QSAM Biosciences Reports Third Quarter 2022 Financial Results and Provides Corporate Update	AQ
14/11/22	QSAM BIOSCIENCES, INC. : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND PLAN OF OPERATIONS (form 10-Q)	AQ
26/10/22	QSAM Biosciences Adds Rutgers Cancer Institute of New Jersey as Clinical Trial Site To Expand and Advance Study of CycloSam® in the Treatment of Bone Cancer	AQ
06/10/22	QSAM BIOSCIENCES, INC. : Unregistered Sale of Equity Securities, Financial Statements and Exhibits (form 8-K)	AQ